Welcome to our shareholder community. Here you will find updates on our innovation pipeline progress, performance results, and corporate milestones. You’ll also have the opportunity to hear from our management team. Sign up now for Pfizer Investor Insights to receive up-to-date information about the company and your investment.

Pfizer continues to invest significant capital in the next generation of potential cancer breakthroughs, having announced its proposed acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Read more

Pfizer delivered solid financial results for the second quarter of 2023, as the company executes on its goal of an unprecedented number of potential new product and indication launches while continuing to advance its pipeline. To date, Pfizer has launched eleven new products and indications, which are expected to contribute to non-COVID operational revenue growth in the second half of 2023 and beyond. Read more

We want to hear from you to help ensure that we are providing content that is informative and relevant.

Submit a question here about Pfizer’s R&D pipeline, Pfizer’s capital allocation objectives, or Pfizer’s roadmap for the future.

In the coming weeks and months, we’ll compile answers to common questions, giving you a way to hear from management on topics of interest to you.